Company intelligence / Profile preview

Medafor

Minneapolis, Minnesota, United Statesmetaphorschool.org ↗

Ownership: Private
Development stage: Commercial

Overview

Medafor developed plant-based microporous polysaccharide hemostatic agents shown to be safe and effective in controlling surgical and topical bleeding. Their flagship product, Arista MPH Hemostat, was indicated as an adjunctive agent when conventional means are ineffective or impractical. Clinical data demonstrated accelerated rate of bleeding control with a strong safety profile.

Therapeutic areas: OtherDermatologyHematology
Modalities: Device (Hemostatic agent)Biologic (Plant-based polysaccharide hemostat)
Industry: Consumable Medical Devices

Drug pipeline

1 asset

MPH

Commercial

Indications: Surgical bleeding, Hemorrhage

Beyond the preview

Go deeper on Medafor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medafor.

Explore the full profile